ENaC Inhibitors and Airway Re-hydration in Cystic Fibrosis: State of the Art

Title:ENaC Inhibitors and Airway Re-hydration in Cystic Fibrosis: State of the Art

Volume: 6

Author(s): Mike Althaus

Affiliation:

Keywords: Airway surface liquid, amiloride, CFTR, cystic fibrosis, ENaC, inhibitor, sodium transport.

Abstract: Cystic fibrosis (CF) is a hereditary disease caused by mutations in the gene encoding the chloride channel “cystic fibrosis transmembrane conductance regulator” (CFTR). The lack of functional CFTR in CF airways leads to impaired ion and fluid homeostasis of the fluid layer which lines the airway surfaces (ASL). The ASL is important for proper ciliary beat and clearance of mucus from the airways. According to the “low volume hypothesis”, CF airway epithelia hyperabsorb sodium via the epithelial sodium channel (ENaC). Although the contribution of ENaC to CF pathogenesis is still under debate, there is convincing data demonstrating that re-hydration of the ASL might improve mucociliary clearance in CF patients. ASL re-hydration might, amongst other things, be achieved by a block of airway transepithelial sodium absorption with inhibitors of ENaC. This mini-review article describes the role of ENaC in ASL fluid homeostasis and rehydration, and summarizes the current state of the art in the discovery and establishment of compounds which inhibit ENaC activity and may represent pharmacological tools for the treatment of CF.

Cite this article as:

Althaus Mike, ENaC Inhibitors and Airway Re-hydration in Cystic Fibrosis: State of the Art, Current Molecular Pharmacology 2013; 6 (1) . https://dx.doi.org/10.2174/18744672112059990025